PriceTargets.com logo

Kymera Therapeutics - KYMR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $53.88
  • Forecasted Upside: 32.52%
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 13 Buy Ratings
  • 1 Strong Buy Ratings
$40.66 As of 12/20/2024 06:16 PM ET
▲ +1.52 (3.88%)

This chart shows the closing price for KYMR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kymera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KYMR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KYMR

Analyst Price Target is $53.88
▲ +32.52% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $53.88, with a high forecast of $74.00 and a low forecast of $30.00. The average price target represents a 32.52% upside from the last price of $40.66.

This chart shows the closing price for KYMR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 18 contributing investment analysts is to moderate buy stock in Kymera Therapeutics. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024BTIG ResearchInitiated CoverageBuy$60.00
12/6/2024BMO Capital MarketsInitiated CoverageMarket Perform$55.00
12/2/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$38.00 ➝ $57.00
11/18/2024StephensInitiated CoverageOverweight$65.00
11/6/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $49.00
11/4/2024UBS GroupLower TargetBuy ➝ Buy$80.00 ➝ $74.00
11/1/2024GuggenheimBoost TargetBuy ➝ Buy$45.00 ➝ $52.00
11/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$54.00 ➝ $53.00
9/27/2024OppenheimerBoost TargetOutperform ➝ Outperform$52.00 ➝ $56.00
9/9/2024Leerink PartnrsUpgradeStrong-Buy
9/9/2024Leerink PartnersReiterated RatingOutperform$60.00
8/26/2024Wolfe ResearchUpgradePeer Perform ➝ Outperform$65.00
8/14/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$34.00 ➝ $45.00
8/12/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$30.00 ➝ $38.00
7/10/2024OppenheimerReiterated RatingOutperform ➝ Outperform$52.00 ➝ $52.00
7/9/2024B. RileyBoost TargetNeutral ➝ Neutral$31.00 ➝ $36.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
5/3/2024OppenheimerLower TargetOutperform ➝ Outperform$53.00 ➝ $52.00
4/22/2024OppenheimerInitiated CoverageOutperform$53.00
3/1/2024Truist FinancialBoost TargetBuy ➝ Buy$41.00 ➝ $54.00
2/27/2024Piper SandlerBoost TargetOverweight ➝ Overweight$39.00 ➝ $56.00
2/23/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$34.00 ➝ $47.00
2/23/2024Stifel NicolausBoost TargetBuy ➝ Buy$35.00 ➝ $55.00
2/15/2024Wolfe ResearchInitiated CoveragePeer Perform
1/4/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
1/3/2024Bank of AmericaDowngradeBuy ➝ Neutral$45.00 ➝ $30.00
12/19/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$26.00
11/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$37.00 ➝ $24.00
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$58.00 ➝ $38.00
11/3/2023HC WainwrightLower TargetBuy ➝ Buy$85.00 ➝ $30.00
10/16/2023Leerink PartnrsReiterated RatingMarket Perform
8/29/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$39.00 ➝ $37.00
8/7/2023Stifel NicolausBoost TargetBuy ➝ Buy$48.00 ➝ $52.00
8/4/2023Credit Suisse GroupBoost TargetNeutral ➝ Neutral$36.00 ➝ $37.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$85.00
6/30/2023Truist FinancialInitiated CoverageBuy$50.00
5/4/2023Raymond JamesUpgradeMarket Perform ➝ Outperform
2/24/2023HC WainwrightReiterated RatingBuy$85.00
2/24/2023Credit Suisse GroupBoost TargetNeutral$32.00 ➝ $39.00
1/3/2023Wells Fargo & CompanyBoost TargetOverweight$40.00 ➝ $42.00
12/19/2022Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $41.00
12/16/2022The Goldman Sachs GroupBoost TargetBuy$40.00 ➝ $52.00
12/15/2022Leerink PartnersBoost TargetMarket Perform$26.00 ➝ $31.00
12/15/2022B. RileyBoost Target$35.00 ➝ $37.00
12/14/2022Piper SandlerBoost Target$43.00 ➝ $58.00
12/5/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$47.00 ➝ $32.00
11/8/2022Wells Fargo & CompanyBoost TargetOverweight$35.00 ➝ $36.00
11/8/2022Raymond JamesInitiated CoverageMarket Perform
11/7/2022B. RileyLower Target$50.00 ➝ $35.00
11/4/2022Morgan StanleyBoost TargetEqual Weight$37.00 ➝ $38.00
11/4/2022Credit Suisse GroupLower TargetOutperform$61.00 ➝ $47.00
8/29/2022Morgan StanleyBoost TargetEqual Weight$35.00 ➝ $37.00
8/15/2022Jefferies Financial GroupInitiated CoverageBuy$40.00
8/10/2022Credit Suisse GroupBoost TargetOutperform$60.00 ➝ $61.00
8/3/2022The Goldman Sachs GroupInitiated CoverageBuy$40.00
7/20/2022Leerink PartnersInitiated CoverageMarket Perform$26.00
6/1/2022Wells Fargo & CompanyLower TargetOverweight$62.00 ➝ $35.00
5/23/2022Piper SandlerLower TargetOverweight$91.00 ➝ $43.00
5/4/2022B. RileyLower Target$67.00 ➝ $50.00
4/28/2022Credit Suisse GroupInitiated CoverageOutperform$63.00
3/10/2022JPMorgan Chase & Co.Initiated CoverageNeutral$44.00
3/2/2022Morgan StanleyLower TargetEqual Weight$68.00 ➝ $66.00
2/10/2022Wells Fargo & CompanyInitiated CoverageOverweight$62.00
12/17/2021HC WainwrightReiterated RatingBuy$85.00
10/13/2021Brookline Capital AcquisitionInitiated CoverageBuy$80.00
10/13/2021Brookline Capital ManagementReiterated RatingBuy$80.00
9/30/2021B. RileyInitiated CoverageNeutral$67.00
9/29/2021Stifel NicolausInitiated CoverageBuy$80.00
9/10/2021Bank of AmericaDowngradeBuy ➝ Neutral$65.00 ➝ $80.00
8/18/2021Morgan StanleyLower TargetEqual Weight$69.00 ➝ $68.00
7/16/2021Morgan StanleyBoost TargetEqual Weight$67.00 ➝ $69.00
5/20/2021UBS GroupInitiated CoverageBuy$80.00
5/18/2021Morgan StanleyLower TargetEqual Weight$69.00 ➝ $67.00
4/14/2021Berenberg BankInitiated CoverageBuy
3/23/2021Morgan StanleyLower TargetEqual Weight$74.00 ➝ $69.00
1/19/2021Morgan StanleyBoost TargetEqual Weight$45.00 ➝ $74.00
12/4/2020HC WainwrightInitiated CoverageBuy
11/24/2020Morgan StanleyBoost TargetEqual Weight$27.00 ➝ $45.00
11/13/2020Piper SandlerInitiated CoverageOverweight
9/15/2020Bank of AmericaInitiated CoverageNeutral$35.00
9/15/2020Morgan StanleyInitiated CoverageEqual Weight$27.00
9/15/2020GuggenheimInitiated CoverageBuy$42.00
9/15/2020CowenInitiated CoverageOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.09 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
5/25/2024
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 13 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 10 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 16 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $40.66
Low: $38.24
High: $40.78

50 Day Range

MA: $46.00
Low: $39.06
High: $51.84

52 Week Range

Now: $40.66
Low: $22.35
High: $53.27

Volume

1,145,939 shs

Average Volume

582,401 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Kymera Therapeutics?

The following Wall Street research analysts have issued stock ratings on Kymera Therapeutics in the last twelve months: B. Riley, Bank of America Co., BMO Capital Markets, BTIG Research, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Stephens, Stifel Nicolaus, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for KYMR.

What is the current price target for Kymera Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Kymera Therapeutics in the last year. Their average twelve-month price target is $53.88, suggesting a possible upside of 32.5%. UBS Group AG has the highest price target set, predicting KYMR will reach $74.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $30.00 for Kymera Therapeutics in the next year.
View the latest price targets for KYMR.

What is the current consensus analyst rating for Kymera Therapeutics?

Kymera Therapeutics currently has 4 hold ratings, 13 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KYMR.

What other companies compete with Kymera Therapeutics?

Other companies that are similar to Kymera Therapeutics include Qiagen, Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S and Revolution Medicines. Learn More about companies similar to Kymera Therapeutics.

How do I contact Kymera Therapeutics' investor relations team?

Kymera Therapeutics' physical mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The company's listed phone number is 857-285-5300 and its investor relations email address is [email protected]. The official website for Kymera Therapeutics is www.kymeratx.com. Learn More about contacing Kymera Therapeutics investor relations.